The first-in-man study of CCS1477 for the treatment of Castrate resistant prostate cancer

Trial Profile

The first-in-man study of CCS1477 for the treatment of Castrate resistant prostate cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Abiraterone (Primary) ; CCS 1477 (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2018 According to a CellCentric media release, this clinical trial has been initiated following regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA).
    • 25 Jun 2018 According to a CellCentric media release, status changed from planning to recruiting.
    • 25 Jun 2018 According to a CellCentric media release, this study is being led by Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top